These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11849659)

  • 1. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia.
    Vohl MC; Szots F; Lelièvre M; Lupien PJ; Bergeron J; Gagné C; Couture P
    Atherosclerosis; 2002 Feb; 160(2):361-8. PubMed ID: 11849659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.
    Couture P; Brun LD; Szots F; Lelièvre M; Gaudet D; Després JP; Simard J; Lupien PJ; Gagné C
    Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):1007-12. PubMed ID: 9633944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
    Heath KE; Gudnason V; Humphries SE; Seed M
    Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.
    Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia.
    Jeenah M; September W; Graadt van Roggen F; de Villiers W; Seftel H; Marais D
    Atherosclerosis; 1993 Jan; 98(1):51-8. PubMed ID: 8457250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations.
    Sijbrands EJ; Lombardi MP; Westendorp RG; Leuven JA; Meinders AE; Van der Laarse A; Frants RR; Havekes LM; Smelt AH
    Atherosclerosis; 1998 Feb; 136(2):247-54. PubMed ID: 9543095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia.
    Gylling H; Aalto-Setälä K; Kontula K; Miettinen TA
    Arterioscler Thromb; 1991; 11(5):1368-75. PubMed ID: 1911722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
    Leitersdorf E; Eisenberg S; Eliav O; Friedlander Y; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Wurm M
    Circulation; 1993 Apr; 87(4 Suppl):III35-44. PubMed ID: 8462179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia.
    Miltiadous G; Xenophontos S; Bairaktari E; Ganotakis M; Cariolou M; Elisaf M
    Pharmacogenet Genomics; 2005 Apr; 15(4):219-25. PubMed ID: 15864114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R).
    Schaefer JR; Kurt B; Sattler A; Klaus G; Soufi M
    Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):2-6. PubMed ID: 22528129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations.
    Torres AL; Moorjani S; Vohl MC; Gagné C; Lamarche B; Brun LD; Lupien PJ; Després JP
    Atherosclerosis; 1996 Sep; 126(1):163-71. PubMed ID: 8879444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia.
    De Knijff P; Stalenhoef AF; Mol MJ; Gevers Leuven JA; Smit J; Erkelens DW; Schouten J; Frants RR; Havekes LM
    Atherosclerosis; 1990 Jul; 83(1):89-97. PubMed ID: 2390138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.
    Ordovas JM; Lopez-Miranda J; Perez-Jimenez F; Rodriguez C; Park JS; Cole T; Schaefer EJ
    Atherosclerosis; 1995 Mar; 113(2):157-66. PubMed ID: 7605354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene.
    Karayan L; Qiu S; Betard C; Dufour R; Roederer G; Minnich A; Davignon J; Genest J
    Arterioscler Thromb; 1994 Aug; 14(8):1258-63. PubMed ID: 8049186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
    Yu L; Qiu S; Genest J
    Atherosclerosis; 1996 Jul; 124(1):103-17. PubMed ID: 8800498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia.
    Larivière M; Lamarche B; Pirro M; Hogue JC; Bergeron J; Gagné C; Couture P
    Atherosclerosis; 2003 Mar; 167(1):97-104. PubMed ID: 12618273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects.
    Raal FJ; Pilcher G; Rubinsztein DC; Lingenhel A; Utermann G
    Atherosclerosis; 1997 Feb; 129(1):97-102. PubMed ID: 9069523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation.
    Dirisamer A; Hachemian N; Bucek RA; Wolf F; Reiter M; Widhalm K
    Eur J Pediatr; 2003 Jun; 162(6):421-5. PubMed ID: 12756561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.